Roth Capital Downgrades GT Biopharma Inc. (GTBP) to Neutral

August 11, 2022 3:31 PM EDT
Get Alerts GTBP Hot Sheet
Price: $1.80 -4.76%

Rating Summary:
    2 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 0 | Down: 1 | New: 4
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Roth Capital analyst Tony Butler downgraded GT Biopharma Inc. (NASDAQ: GTBP) from Buy to Neutral with a price target of $3.00 (from $9.00).

The analyst comments "GT Biopharma provided a Q2 business update. GTBP develops tri- and tetraspecific NK cell engagers (TriKE, TetraKE) that are cytotoxic to a number of cancers. First-gen TriKEs showed efficacy signals against acute myeloid leukemia blasts. GTBP has shifted gears to develop second-gen TriKEs given the increased anti-cancer potency of these molecules, which we have characterized in a number of prior notes. We had expected an IND filing from the first of the second-generation TriKEs (GTB-3650) in mid-2022. However, this is being pushed back almost one year until 2023. While we are enthusiastic about the program, the delay leads us to move our rating to Neutral and our PT to $3, until clarity on the IND filing becomes evident. Endof-quarter cash balance was $23.7M."

For an analyst ratings summary and ratings history on GT Biopharma Inc. click here. For more ratings news on GT Biopharma Inc. click here.

Shares of GT Biopharma Inc. closed at $2.87 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change, Downgrades

Related Entities

Roth Capital